QleanAir AB, Swedish provider of solutions for clean indoor air, has announced receiving an order worth $630,000 from a major university health and research organisation to provide a cleanroom for research within cell and gene therapy.
The order is a result of a previously announced letter of intent from a major university health and research organisation. The GMP classified cleanroom will be used for research and production within cell and gene therapy. Construction for the cleanroom will begin late Q1 and will end within Q2.
“QleanAir is carefully and diligently working its way into markets new to the US business. This is one more step towards broadening our scope in providing high quality clean spaces in the US. It’s especially exciting to do so with such a high profile and prestigious client,” said Zachary Douglas, President of QleanAir Scandinavia.